Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes
23/07/2026 04:52
Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes July 23 (Reuters) - Shares of Dr Reddy's Laboratories REDY.NS declined 4.4% on Thursday after brokerages cut their earnings forecasts for the Indian drugmaker after weaker-than-expected quarterly results and semaglutide supply disruptions.
The stock was trading at 1,130 rupees, its lowest in over one year, and was the top loser on the pharma index .NIPHARM and the Nifty 50 .NSEI.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
((Kashish.Tandon@thomsonreuters.com; 8800437922;))
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption